Questo studio, effettuato con elettroretinogramma multifocale su 31 occhi affetti da diverse patologie, conferma la mancanza di tossicità nei confronti dei fotorecettori della terapia intravitreale con Bevacizumab (Avastin).

Retina the journal of retinal and vitreous diseasesMultifocal Electrophysiologic Findings After Intravitreal Bevacizumab (Avastin) Treatment

Torres-Soriano, Mitzy E. MD; Cubas-Lorenzo, Victoria MD; García-Aguirre, Gerardo MD; Hernández-Rojas, Myrian MD; Kon-Jara, Verónica MD; Díaz-Rubio, JoséLuis MD; Fromow-Guerra, Jans MD; Quiroz-Mercado, Hugo MD; Jiménez-Sierra, Juan M. MD

May 2012 – Volume 32 – Issue 5 – p 972–976

Purpose: To determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography testing.

Methods: Thirty-one eyes with choroidal neovascularization, proliferative diabetic retinopathy, and retinal vein occlusion received intravitreal bevacizumab (2.5 mg/0.1 mL). All patients underwent best-corrected visual acuity measurement, retinal fluorescein angiography, optical coherence tomography, and multifocal electroretinography at baseline and 1 month after the treatment.

Results: Subjects undergoing multifocal electroretinography testing had no statistically significant changes in electrophysiologic responses 1 month after the intravitreal injection of bevacizumab.

Conclusion: Multifocal electrophysiologic testing did not demonstrate any short-term cone photoreceptor toxicity after intravitreal bevacizumab.